| |
| |
|
| Insider
Information: |
Dekkers Marijn E |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
535,970 |
|
|
Indirect Shares
|
6,717,950 |
|
|
| Direct
Value |
$27,316,827 |
|
|
|
Indirect Value
|
$68,823,189 |
|
|
| Total
Shares |
7,253,920 |
|
|
| Total
Value |
$96,140,016 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 38.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Thermo Fisher Scientific |
TMO |
Chief Executive Office... |
2009-08-17 |
42,554 |
2009-08-17 |
60,260 |
Premium* |
|
|
Biogen Idec Inc |
BIIB |
Director |
2009-06-03 |
6,595 |
2007-05-31 |
0 |
Premium* |
|
|
General Electric Co |
GE |
Director |
2017-04-24 |
1,000 |
2017-04-24 |
40,000 |
Premium* |
|
|
Quanterix Corp |
QTRX |
|
2021-06-07 |
2,270 |
2020-08-07 |
0 |
Premium* |
|
|
Cerevel Therapeutics Holdings, I... |
CERE |
Director |
2023-06-07 |
31,822 |
2023-06-07 |
602,326 |
Premium* |
|
|
Highcape Capital Acquisition Corp. |
QSI |
Director |
2021-06-11 |
170,512 |
2021-06-10 |
500,000 |
Premium* |
|
|
Ginkgo Bioworks Holdings, Inc |
DNA |
Director |
2024-05-16 |
281,217 |
2024-05-16 |
5,515,364 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
97 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| QTRX |
Quanterix Corp |
|
– • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,270 |
6,810 |
0 |
- |
|
| QTRX |
Quanterix Corp |
|
– • – |
2020-08-07 |
4 |
S |
$32.49 |
$897,341 |
I/I |
(27,619) |
0 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • – |
2020-10-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,540 |
|
% |
|
| QTRX |
Quanterix Corp |
|
– • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,270 |
9,080 |
0 |
- |
|
| QTRX |
Quanterix Corp |
|
– • – |
2021-01-11 |
4 |
AS |
$47.17 |
$2,187,514 |
D/D |
(44,962) |
9,080 |
0 |
% |
|
| QTRX |
Quanterix Corp |
|
– • – |
2021-01-11 |
4 |
OE |
$8.16 |
$498,978 |
D/D |
44,962 |
54,042 |
0 |
- |
|
| QTRX |
Quanterix Corp |
|
– • – |
2021-06-04 |
4 |
OE |
$8.16 |
$89,164 |
D/D |
5,119 |
14,199 |
0 |
- |
|
| QTRX |
Quanterix Corp |
|
– • – |
2021-06-04 |
4 |
AS |
$55.05 |
$418,918 |
D/D |
(7,610) |
6,589 |
0 |
% |
|
| QTRX |
Quanterix Corp |
|
– • – |
2021-06-07 |
4 |
OE |
$23.12 |
$109,404 |
D/D |
4,732 |
11,321 |
0 |
- |
|
| QTRX |
Quanterix Corp |
|
– • – |
2021-06-07 |
4 |
AS |
$55.58 |
$506,160 |
D/D |
(9,051) |
2,270 |
0 |
% |
|
| QSI |
Highcape Capital Acquisit... |
Director |
– • – |
2021-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
0 |
- |
|
| QSI |
Highcape Capital Acquisit... |
Director |
– • – |
2021-06-10 |
4 |
A |
$10.00 |
$5,000,000 |
I/I |
500,000 |
500,000 |
0 |
- |
|
| QSI |
Highcape Capital Acquisit... |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
20,512 |
170,512 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2021-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
374,960 |
374,960 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2021-09-16 |
4 |
A |
$0.00 |
$0 |
I/I |
5,780,364 |
5,780,364 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • – |
2021-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,270 |
42,810 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2022-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,746,706 |
2,121,666 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
70,921 |
2,192,587 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2022-11-03 |
4 |
AS |
$2.56 |
$438,925 |
D/D |
(171,455) |
2,021,132 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
31,822 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
• • – |
2024-05-14 |
4 |
S |
$0.93 |
$1,606,162 |
D/D |
(1,727,056) |
281,217 |
0 |
% |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
• • – |
2024-05-16 |
4 |
S |
$0.83 |
$220,030 |
I/I |
(265,000) |
5,515,364 |
0 |
% |
|
97 Records found
|
|
Page 4 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
